Alterity Therapeutics CEO to Present ATH434 Drug Development Update

Alterity Therapeutics has submitted a Form 6-K to announce an upcoming corporate update regarding ATH434, their key therapeutic candidate.

Rhea-AI Filing Summary

Alterity Therapeutics has submitted a Form 6-K to announce an upcoming corporate update regarding ATH434, their key therapeutic candidate. The filing indicates that CEO Geoffrey P. Kempler will provide details about the company's progress through Exhibit 99.1.

Key points from this filing include:

• Filed as a foreign private issuer under Rule 13a-16/15d-16
• Company files annual reports under Form 20-F
• Filing will be incorporated into multiple registration statements including Form S-8 (Files No. 333-251073, 333-248980, 333-228671) and Form F-3 (Files No. 333-274816, 333-251647, 333-231417, 333-250076)
• Document signed by Geoffrey P. Kempler in his capacity as Chairman

This filing suggests potential material developments regarding ATH434, which could be significant for investors following Alterity's drug development pipeline. The corporate update may include clinical progress, regulatory developments, or other strategic initiatives related to their therapeutic program.

FAQ

What type of SEC filing did ATHE submit on June 28, 2025?

ATHE submitted a Form 6-K (Report of Foreign Private Issuer) on June 28, 2025. The filing indicates that CEO will provide a corporate update specifically focused on ATH434.

Who is the current Chairman of Alterity Therapeutics (ATHE)?

According to the Form 6-K filing, Geoffrey P. Kempler serves as the Chairman of Alterity Therapeutics Limited, as evidenced by his signature on the document dated June 23, 2025.

What registration statements is ATHE's Form 6-K being incorporated into?

The Form 6-K is being incorporated into ATHE's Registration Statement on Form S-8 (Files No. 333-251073, 333-248980 and 333-228671) and Registration Statements on Form F-3 (Files No. 333-274816, 333-251647, 333-231417 and 333-250076).

Where is ATHE's principal executive office located?

Alterity Therapeutics Limited's principal executive office is located at Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia.

What is the purpose of ATHE's June 2025 Form 6-K filing?

The primary purpose of this Form 6-K filing is to announce that Alterity's CEO will provide a corporate update regarding ATH434, as indicated in Exhibit 99.1 of the filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/23/2025 - 08:00 AM Learn about SEC filing dates

 

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-163

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of June 2025

 

Alterity Therapeutics Limited

(Name of Registrant)

 

Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia

(Address of Principal Executive Office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒       Form 40-F ☐

 

This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073, 333-248980 and 333-228671) and our Registration Statements on Form F-3 (Files No. 333-274816, 333-251647, 333-231417 and 333-250076)

 

 

 

 

 

 

ALTERITY THERAPEUTICS LIMITED

(a development stage enterprise)

 

The following exhibits are submitted:

 

99.1   Alterity CEO to Provide Corporate Update on ATH434

 

1

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 	Alterity Therapeutics Limited
 	 	 
 	By:	/s/ Geoffrey P. Kempler
 	 	Geoffrey P. Kempler
 	 	Chairman

 

Date: June 23, 2025

 

2